 | | The novel azoles (e.g., voriconazole, posaconazole, or ravuconazole), glucan synthesis inhibitors (e.g., caspofungin, V-echinocandin, FK463) and liposomal nystatin are active in vitro against Aspergillus and remain promising for future therapy of aspergillosis [122, 579, 683, 890, 1091, 1129, 1152, 1434, 1569, 2352]. |